Newsletter | June 4, 2026

06.04.26 -- FDA Now A Supply-Chain Complication

SPONSOR

Where Formulation Expertise Connects

As pipelines grow more complex and timelines become more ambitious, companies increasingly rely on strong external partners to advance their drug products efficiently and with reduced risk. This is where integrated expertise in formulation development, analytical characterization, and CMC strategy becomes a key enabler for successful partnerships. The BIO International Convention in San Diego is one of the leading global partnering events for the biotech and pharmaceutical industry, bringing together innovators, decision-makers, and service providers to build meaningful collaborations. Learn more.

INDUSTRY INSIGHTS

Key Features Of An Effective Medical Information Service

Canada’s medical info requires professionalism, compassion, and local expertise. Larry Hough highlights bilingual support, accurate responses from qualified healthcare professionals, and advanced systems.

How Proactive Regulatory Planning Supports Improved Drug Formulation

Integrating regulatory strategy with R&D planning early in drug development helps to minimize formulation risks and align manufacturing with compliance while preventing costly delays.

Digital Innovation And Sustainability Are Redefining Biomanufacturing

Next Generation Manufacturing (NGM) integrates advanced process design, digital innovation, and strategic facility planning to facilitate agile, efficient, and sustainable biopharmaceutical production.

FEATURED EDITORIAL

FDA Now A Supply-Chain Complication

Biopharma outsourcing is impacted by geopolitics and government policy. COVID. BIOSECURE Act. Trump’s tariffs. China chicanery. Europe’s repositioning. South Korea’s rise. India’s widening role. And now we seem to be crossing the Rubicon to FDA regulatory discontinuity impacting our supply chains. How is the FDA currently impacting development and manufacturing outsourcing?

Mapping Candel Therapeutics' Sprint To The BLA Finish Line

Leaders from the adenovirus/prodrug developer discuss the complex balancing act of preparing to scale up for commercial manufacturing without overextension.

INDUSTRY INSIGHTS CONTINUED

Analytical Approach For Bispecific Antibody Quality Study

Bispecific antibody quality control demands advanced analytics to detect mispaired species, assess structural integrity, and confirm potency, ensuring safety and efficacy across therapeutic applications.

From Day One Success To Everyday Improvement: The OR → OE Continuum

Bridging the gap between startup and long-term sustainability requires a strategy. Learn to transform early readiness metrics into a durable operating system that drives performance improvements.

Accelerating A Complex Molecule From CLD To cGMP In 12 Months

Assimilate how to mitigate technical risk, implement parallel process development, and design custom purification strategies for highly sensitive novel modalities to accelerate to cGMP material.

Biomanufacturing Readiness: A Validation Model For Multiproduct Facilities

Optimize your validation strategy to meet evolving regulatory demands and product complexities with a scalable, efficient framework that accelerates facility readiness and ensures consistent quality.

Humanization Of High Affinity Therapeutic Antibodies

Here, we present a hybridoma-based antibody discovery and humanization strategy for a T1P target, utilizing Penta Mice immunization to generate monoclonal antibodies.

Optimizing Biotherapeutic Protein Expression With CHO Vector Technology

Review the development of a high-strength synthetic gene promoter that enhances titers while maintaining exceptional product quality and expression stability, to support biomanufacturing.

High Purity Alcohols In Biopharma: Insights In Navigating Compliance

Uncover how to mitigate supply chain risks for industrial alcohols and ensure workplace safety through rigorous tracking and reporting protocols.

Shelf Cooling Rate Effects On Ice Nucleation Temperature

Freezing conditions shape ice structure, mass transfer resistance, and drying efficiency. Data shows how cooling rate, vial size, and nucleation interact to optimize freeze-drying.

LYO Cycle Development Ensures Success For Oncology Drug Scale-Up

An optimized lyophilization cycle removes excess moisture during scale‑up by adjusting drying for larger equipment, improving stability, maintaining efficiency, and supporting clinical validation.

SPONSOR

Webinar: Cracking complexity: Learnings from 70+ bispecific antibody programs

Discover how early-stage biotech teams can reduce risk and accelerate bispecific antibody development in this webinar from Lonza. Drawing on insights from 70+ programs, Lonza experts explore key challenges across analytical development, downstream purification, and formulation, while sharing practical strategies to support IND readiness, avoid costly delays, and confidently advance complex biologics toward the clinic with greater speed and long-term success. Click here to learn more.

SOLUTIONS

USP <382> Functional Suitability & CCI Testing

Early Developability Assessment For Smarter Antibody Selection

Expertise At Every Step

Reducing CMC Risk With Proven Analytical And Formulation Expertise

Sterile Drug Product Development And Manufacturing

Access To Medicine In A Way The Industry Hasn't Seen Before

OUTSOURCED PHARMA CAPABILITIES UPDATE

Find Your New CDMO At Outsourced Pharma Capabilities Update

CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.

Connect With Outsourced Pharma: